Gapping up
In reaction to strong earnings/guidance:
- PHG +6%, HAL +4.7%, LII +4.2%
M&A news:
- DNR +143.5% (receives corporate buyout offer for $1.20 per share)
- NBL +9.5% (to be acquired by Chevron (CVX) for $10.38/share)
Other news:
- BTAI +32.1% (announces BXCL501 met the primary and secondary endpoints of SERENITY I and SERENITY II)
- BNTX +11% (BioNTech and Pfizer (PFE) to supply 30 mln doses of mRNA-based vaccine candidate against SARS-CoV-2 to UK)
- ASMB +4.8% (Assembly Biosciences and BeiGene (BGNE) have entered into a collaboration in China for Assembly's portfolio of three clinical-stage core inhibitor candidates for the treatment of patients with chronic hepatitis B virus (HBV) infection)
- QDEL +4.4% (Quidel's Sofia SARS Antigen FIA receives CE Mark)
- BABA +3.8% (commenced the process of a concurrent listing and IPO on the Shanghai Stock Exchange's STAR board and The Stock Exchange of Hong Kong Limited)
- DGX +3.8% (receives emergency use authorization use specimen pooling with its proprietary molecular diagnostic test for COVID-19) LMNX +3.8% (receives Emergency Use Authorization from FDA for COVID-19 antibody test)
- OFIX +3.6% (receives FDA clearance and European CE Mark approval for the JuniOrtho Plating System)
- PFE +3.5% (BioNTech and Pfizer (PFE) to supply 30 mln doses of mRNA-based vaccine candidate against SARS-CoV-2 to UK)
- GRFS +3.5% (acquires Green Cross plasma fractionation facility for $460 mln)
- KPTI +3.5% (receives FDA acceptance of filing of supplemental NDA for XPOVIO as a new treatment for patients with multiple myeloma after at least one prior line of therapy)
- QTNT +3.1% (reported that an independent study conducted in Madrid, Spain has confirmed the high performance characteristics of the Company's MosaiQ COVID-19 Antibody Microarray)
- OSMT +3% (announces FDA user fee goal date of December 29, 2020 for arbaclofen extended release tablets)
- ORTX +2.9% (received both orphan drug designation and rare pediatric disease designation from the FDA for OTL-203 for the treatment of mucopolysaccharidosis type I (MPS-I))
- ASHR +2.7% (rising with Shanghai closing up 3% overnight)
Analyst comments:
- QEP +7.5% (upgraded to Neutral from Underweight at JP Morgan)
- DBX +3.8% (upgraded to Buy from Hold at Jefferies)
- LPI +2.1% (upgraded to Outperform from Mkt Perform at Raymond James)
- CTXS +1.8% (upgraded to Overweight from Equal Weight at Barclays)
- ZYXI +1.8% (initiated with an Overweight at Piper Sandler)
- APA +1.4% (upgraded to Outperform from Mkt Perform at Raymond James)
- CAH +1.2% (upgraded to Buy from Neutral at Guggenheim)
- MELI +1.1% (upgraded to Outperform from Neutral at Bradesco BBI)